Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alto Neuroscience, Inc. Common Stock (NY:ANRO)

7.500 +1.420 (+23.36%)
Streaming Delayed Price Updated: 9:42 AM EDT, Oct 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Alto Neuroscience, Inc. Common Stock

12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Alto Neuroscience Stock Soars After FDA Grants Fast Track Designation To Schizophrenia Drug
FDA’s Fast Track designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and fill an unmet medical need. 
Via Stocktwits
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
This Electronic Arts Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
This VSE Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings... 
Via Benzinga
Alto Neuroscience Posts Q2 Net Loss
Via The Motley Fool
Alto Neuroscience Adds 'Intriguing' Depression Asset Via Over $100 Million Deal
Alto Neuroscience acquires Chase's treatment-resistant depression drug portfolio for $1.75 million upfront; early data shows strong efficacy for lead candidate ALTO-207. 
Via Benzinga
Alto Neuroscience Is Down Nearly 35% This Year, But Retail Traders Keep Flocking To Micro-Cap Stock
While ALTO-100's Phase 2 results failed to meet expectations, the company has emphasized the potential of ALTO-300, another MDD treatment currently in Phase 2b trials. 
Via Stocktwits
This Addus HomeCare Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
 
Via Benzinga
Nasdaq Down 2%; US Crude Stocks Increase
 
Via Benzinga
Neuropsychiatry-Focused Alto Neuroscience's Mid-Stage Depression Trial Disappoints, Analyst Notes Failure Raises Concerns About Platform
Alto Neuroscience's ALTO-100 Phase 2b study for major depressive disorder failed to meet its primary endpoint, but the company plans further data analysis and studies. 
Via Benzinga
Gold Moves Lower; AT&T Earnings Top Views
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
Dow Tumbles Over 250 Points; Boeing Posts Q3 Loss
 
Via Benzinga
Topics Stocks
Enphase Energy Posts Downbeat Results, Joins McDonald's, Seagate And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
Why Stride Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
ANRO Stock Earnings: Alto Neuroscience Beats EPS for Q2 2024
ANRO stock results show that Alto Neuroscience beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Wake Up! 3 Lesser-Known Stocks Investors Are Sleeping On
Under-the-radar stocks offer incredible chances at massive returns with these shares representing compelling choices for investors. 
Via InvestorPlace
ANRO Stock Earnings: Alto Neuroscience Misses EPS for Q1 2024
ANRO stock results show that Alto Neuroscience missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Treatment Patch For Schizophrenia: Newly Listed Alto Neuroscience Is Uniquely Positioned In Neuropsychiatry Landscape
Alto Neuroscience reported positive results for its novel PDE4 inhibitor in a Phase 1 study for cognitive impairment associated with schizophrenia. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
The biggest pre-market stock movers are starting off the trading week as we check out all of the hottest news for Monday morning! 
Via InvestorPlace
Maker Of Wilson Tennis Rackets Raises $1.37 Billion In Discounted IPO
Amer Sports, the maker of Wilson tennis rackets and a host of other sports equipment, raised about $1.37 billion in its initial public offering, which was priced below the previously expected $16-$18... 
Via Talk Markets
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.